Huntington's disease, Amyotrophic Lateral Sclerosis, X-linked Dystonia-parkinsonism, Neurodegenerative disorders, Human genetic disorders
UCI Chancellor's Fellow (2014-2017)
Chancellor's Professor, University of California, Irvine (2018-2023)
Donald Bren Professor, University of California, Irvine (2020 - present)
The Thompson laboratory has been actively engaged in investigating the fundamental molecular and cellular events that underlie how the mutant Huntington’s disease gene causes degeneration of specific brain cell populations to induce motor and cognitive decline and premature death of patients with the ultimate goal to develop new therapeutic approaches. HD was one of the first neurodegenerative diseases for which a genetic cause was determined, and has served as a paradigm for researchers to study other such diseases. HD is an autosomal dominant neurodegenerative disease characterized by specific regions of neuronal dysfunction and loss, most notably of neurons in the striatum and cortex. The primary cause of HD is the expansion of a CAG triplet repeat encoding a polyglutamine (polyQ) tract within the amino terminal portion of the Huntingtin (Htt) protein. The mutation disrupts many cellular processes, including transcriptional regulation, vesicular trafficking, mitochondrial function, autophagic clearance, and protein modification, among others. The laboratory also focuses on understanding casual mechanisms that underlie Amyotrophic Lateral Sclerosis and more recently, X-linked Dystonia-Parkinsonism with the goal of developing treatment options for the disease. The research benefits from the integrated use of patient iPSCs and mouse models of disease together with the studies of RNA biology and network-based bioinformatics.
National Medical Research Award of the National Health Council (1993)
Hereditary Disease Foundation Lieberman Award (1997-1999)
UCI College of Medicine, AMWA Gender Equity Award (1999)
UCI College of Medicine, Silver Beaker award to the Outstanding Basic Science Faculty Member (1999)
Distinguished Assistant Professor Award for Research, UC Irvine (2002)
Huntington’s Disease Society of America Distinguished Leadership Award (2002)
UCI College of Medicine, Excellence in Teaching (2004-2007,09,11-14,16,17)
Founding Co-editor in Chief, Journal of Huntington’s Disease (2012 - present)
Leslie Gehry Brenner Award for Innovation in Science, Hereditary Disease Foundation (2013)
Chancellor’s Award for Excellence in Fostering Undergraduate Research (2014)
Elected AAAS Fellow (2013)
UCI Big Ideas Challenge – Co-winner
Dr. Thompson completed her PhD in 1989 at UCI and became a faculty member in 2000. Dr. Thompson has studied Huntington’s disease (HD) for most of her scientific career and was a member of the international consortium that identified the causative gene for HD in 1993 while a postdoctoral fellow in the UCI laboratory of Dr. John Wasmuth. She also co-identified the mutation causing achondroplasia, the most common genetic form of short-limbed dwarfism in 1994. Dr. Thompson was one of the founders of the HD patient clinic at UCI, is a member of the Huntington Study Group Scientific Affairs Committee and Enroll-HD Clinical Trial Committee, which are each involved in HD clinical trials, is part of the UCI HDSA Center of Excellence, and is very active in the HD community. Dr. Thompson is a member of the Hereditary Disease Foundation HD Cure Committee, HD CARE Scientific Advisory Board (SAB), Huntington’s Disease Society of America SAB Chair and member board of trustees and is founding Co-Editor in Chief of the Journal of Huntington’s Disease. She also is a member of Scientific Advisory Panels for neural stem cell therapy programs in Italy and Spain and on the SAB for Target ALS and the ALS Packard Center at Johns Hopkins University.
Morozko, E.L., Ochaba J., Hernandez S., Lau A., Sanchez I., Orellana I., Kopan L., Overman J., Yeung S., Steffan J.S., Reidling J., and Thompson L.M. (2018). Comprehensive Biochemical Analysis of Protein Homeostasis in R6/2 Mice. J. Huntington’s Dis. 7:321-335. doi: 10.3233/JHD-180329.
Eva L. Morozko,*, Charlene Smith-Geater, *, Alejandro Mas Monteys, Subrata Pradhan, Ryan G. Lim, Peter Langfelder, Marketta Kachemov, Austin Hill, Jennifer T. Stocksdale, Pieter R. Cullis, Jie Wu, Joseph Ochaba, Ricardo Miramontes, Anirban Chakraborty, Tapas K. Hazra, Alice Lau, Sophie St-cyr, Illiana Orellana, Lexi Kopan, Keona Q. Wang, Sylvia Yeung, Blair R. Leavitt, Jack C. Reidling, X. William Yang, Joan S. Steffan, Beverly L. Davidson, #, Partha S. Sarkar, #, Leslie M. Thompson # (2020). PIAS1 modulates striatal transcription, SUMOylation, and DNA damage repair with relevance to Huntington’s disease. PNAS (in press)
The NeuroLINCS Consortium (list of consortium groups, Thompson as co-corresponding author) (2020). An integrated multi-omic analysis in iPSC-derived motor neurons from C9ORF72 ALS patients. BioRxiv https://biorxiv.org/cgi/content/short/2020.11.01.362269v1
Chow, DS, Glavis-Bloom, J, Soun, JE, Weinberg, B, Loveless, TB, Xie, X, Matusa, S., Monuki, E, Park JI, Bota, D, Wu, J, Thompson, L, Boden-Albala B, Khan, S, Amin, AN, Chang, PD (2020). Development and external validation of a prognostic tool for COVID-19 critical disease. PLoS One Dec 9;15(12):e0242953. doi: 10.1371/journal.pone.0242953. PMID: 33296357
Dewan R, Chia R, Ding J, Hickman RA, Stein TD, Abramzon Y, Ahmed S, Sabir MS, Portley MK, Tucci A, Ibáñez K, Shankaracharya FNU, Keagle P, Rossi G, Caroppo P, Tagliavini F, Waldo ML, Johansson PM, Nilsson CF; American Genome Center TAGC); FALS Sequencing Consortium; Genomics England Research Consortium; International ALS/FTD Genomics Consortium (iAFGC); International FTD Genetics Consortium (IFGC); International LBD Genomics Consortium (iLBDGC); NYGC ALS Consortium*; PROSPECT Consortium, Rowe JB, Benussi L, Binetti G, Ghidoni R, Jabbari E, Viollet C, Glass JD, Singleton AB, Silani V, Ross OA, Ryten M, Torkamani A, Tanaka T, Ferrucci L, Resnick SM, Pickering-Brown S, Brady CB, Kowal N, Hardy JA, Van Deerlin V, Vonsattel JP, Harms MB, Morris HR, Ferrari R, Landers JE, Chiò A, Gibbs JR, Dalgard CL, Scholz SW, Traynor BJ. (2020). Pathogenic Huntingtin Repeat Expansions in Patients with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis Neuron. Nov 25:S0896-6273(20)30883-7. doi: 10.1016/j.neuron.2020.11.005. Online ahead of print.PMID: 33242422 *member of NYGC ALS Consortium.
Smith-Geater, C.*, Hernandez, S.J.*, Lim, R.G., Adam, M., Wu, J. Stocksdale, J.T. Wassie, B.T., Gold, M.P., Wang, K.Q., Miramontes, R., Kopan, L., Orellana, I., Joy, S., Kemp, P.J., Allen, N.D., Fraenkel, E#., Thompson, L.M#. (2020). Aberrant development corrected in adult-onset Huntington's disease iPSC-derived neurons via WNT signaling modulation. Stem Cell Reports 10;14(3):406-419. doi: 10.1016/j.stemcr.2020.01.015. Epub 2020 Feb 27.
Kedaigle, A.J.*, Reidling, J.C.*, Lim, R.C.*, Adam, A., Wassie, B, Stocksdale, J.T., Wu, J., Casale, M.S., Fraenkel, E.,#, and Thompson, L.M.,# (2020). Treatment with JQ1, a BET bromodomain inhibitor, is selectively detrimental to R6/2 Huntington’s disease mice. Hum. Mol. Genet. Jan 15;29(2):202-215.
Crapser, J., Ochaba, J., Soni, N., Reidling, J.C., Thompson, L.M.*, Green, K.* (2020).
Microglia facilitate brain volume loss and extracellular matrix changes in the R6/2 mouse model of Huntington’s disease. * co-senior authors. Brain. Jan 1;143(1):266-288.
Gao, R. Chakraborty, A., Geater, C., Pradhan, S. Gordon, K.L., Snowden, J., Yuan, S., Dickey, A.S., Choudhary, S.,Ashizawa, T., Ellerby, L.M. La Spada, A.R., Thompson, L.M., Hazra, T.K, and Sarkar, P.S. (2019). Mutant huntingtin impairs PNKP and ATXN3, disrupting DNA repair and transcription. eLife Apr 17;8. pii: e42988. doi: 10.7554/eLife.42988.PMID: 30994454
Ochaba, J., Fote, G., Kachemov, M. Thein, S. Yeung, S.Y., Lau, A.L., Hernandez, S.
Lim, R.G., Casale, M., Neel, M.J., Monuki, E.J., Reidling, J.,Housman, D.E.,
Thompson, L.M. and Steffan, J.S. (2019). IKKß slows Huntington's Disease progression
in R6/1 Mice. Proc. Natl. Acad. Sci USA May 28;116(22):10952-10961. doi: 10.1073/pnas.1814246116.
Conlon EG, Fagegaltier D, Agius P, Davis-Porada J, Gregory J, Hubbard I, Kang K, Kim D; New York Genome Center ALS Consortium, Phatnani H, Kwan J, Sareen D, Broach JR, Simmons Z, Arcila-Londono X, Lee EB, Van Deerlin VM, Shneider NA, Fraenkel E, Ostrow LW, Baas F, Zaitlen N, Berry JD, Malaspina A, Fratta P, Cox GA, Thompson LM, Finkbeiner S, Dardiotis E, Miller TM, Chandran S, Pal S, Hornstein E, MacGowan DJ, Heiman-Patterson T, Hammell MG, Patsopoulos NA, Dubnau J, Nath A, Phatnani H, Shneider NA, Manley JL.(2018). Unexpected similarities between C9ORF72 and sporadic forms of ALS/FTD suggest a common disease mechanism. elife. 2018 Jul 13;7. pii: e37754. doi: 10.7554/eLife.37754.PMID:30003873
NIH R35 NS116872 (Thompson, PI) 05/01/20-04/30/28
Molecular Mechanisms of Pathogenesis in Huntington’s disease.
The R35 integrates our ongoing and proposed studies to investigate pathogenic mechanisms in HD. These studies are broadly focused on protein homeostasis, DNA damage and repair and epigenomics.
PACKARD FOUNDATION (Rothstein, PI 10/1/2017-12/31/2023
(Thompson OMICS PI). Answer ALS
The goals are to build a comprehensive clinical, genetic, molecular and biochemical assessment of ALS and to openly share the results with the global research community.
Collaborative Center for X-linked Dystonia Parkinsonism (CCXDP). 10/1/19-9/30/21 (Thompson, Finkbeiner, MPI).
Molecular and cellular mechanisms of XDP using patient-derived neuronal models
The goals are to elucidate mechanisms and integrated signatures from iPSC-derived neuronal models of XDP (in collaboration with Steven Finkbeiner, Gladstone/UCSF).
CHDI Foundation 10/1/19 – 3/31/21
NeuroLINCS for HD
The goals are to identify integrated signatures from differentiated iPS cells from HD and control subjects.
P01 NS084974-06A1 (PI Len Petrucelli; Thompson Core Leader) 04/01/20-03/31/25
Pathobiology of Neurodegeneration in C9ORF72 repeat expansion.
The goals of the Bioinformatics and Biostatistics core are to develop a standardized set of descriptors and parameters appropriate for data harmonization and standard formats for raw data and processed data.
R61HL154307 (PI Christopher Hughes, Thompson MPI) 09/03/20 – 08/31/25
A Vascularized Micro-Organ platform for the study of Brain-BBB-Blood Interaction
The goals are to develop a micro-organ platform to study human BBB interactions in control and neurodegenerative disease context derived from human iPSCs.
Chan Zuckerberg Initiative (Thompson, Spitale MPI) 12/1/20-5/31/22
Collaborative Pairs. Longitudinal full-length, single molecule RNA analysis in neurodegenerative disease
The goals are to employ innovative approaches to analysis of RNA expression and post-transcriptional modification to gain novel insights into changes in RNA sequence and structure. These studies will broadly inform RNA biology across neurodegenerative diseases
T32 NS082174-01 (Thompson, Donovan MPI) 7/1/2013-6/30/2023
NIH/NINDS . Training Program in Stem Cell Translational Medicine for Neurological Disorders
The major goal of this project is to train Predoctoral students in integrated and translational approaches to stem cell biology, neuroscience and human neurological disease.
Society for Neuroscience
American Society of Human Genetics
American Association for the Advancement of Science
American Society for Neural Therapy and Repair
American Heart Association
Fellow, UCI MIND
Faculty, Sue and Bill Gross Stem Cell Center
Venezuela Huntington’s Disease Project Participant
NIH LINCS Consortium member
Interdepartmental Neuroscience Program
Cellular and Molecular Biosciences
Sue and Bill Gross Stem Cell Center
Center for the Neurobiology of Learning and Memory (CNLM)